Updated NCCN guidelines for multiple myeloma add dedicated recommendations for MRD testing, prefer tests that can detect one cancer cell among 1 million cells and expand when testing should occur.
|Videos|July 29, 2016
Bridging the Researcher-Patient Gap
Author(s)Karuppiah Kannan
Karuppiah Kannan, associate director at Takeda Pharmaceuticals, discusses what it was like as a researcher to meet with patients during the Moving Mountains for Multiple Myeloma Grand Canyon hike.
Advertisement
Karuppiah Kannan, associate director at Takeda Pharmaceuticals, discusses what it was like as a researcher to meet with patients during the Moving Mountains for Multiple Myeloma Grand Canyon hike.
Patients and researchers are on two ends of the treatment spectrum, who, though they rarely meet, cannot exist without the other.
Advertisement
Related to this article
Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Talvey and Darzalex combinations helped patients with relapsed multiple myeloma live longer without disease progression in the phase 3 MonumenTAL-3 trial.
Advertisement
Advertisement